{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:42:06Z","timestamp":1791582126854,"version":"4.3.4"},"reference-count":57,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,10]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Bedaquiline (BDQ), delamanid (DLM) and pretomanid (Pa) were widely used in recent years. This study aimed to analyse adverse drug event (ADE) reports associated with them based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database, to explore the signals of ADEs and provide reference for clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective pharmacovigilance study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The FAERS database was extracted from 2015 to 2023, and the ADE reports about BDQ, DLM, and Pa were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Data mining was carried out on relevant reports of BDQ, DLM, and Pa using the reporting odds ratio (ROR), proportional reporting ratio (PRR), medicines and healthcare products regulatory agency (MHRA) and the information component (IC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 4010 ADE reports were included: 2477 for BDQ, 1360 for DLM and 173 for Pa. Combined with disproportionality analysis in different backgrounds, the salient risks of three target drugs varied. In the entire dataset, prolonged ECG QT (BDQ: ROR=42.57; DLM: ROR=28.00; Pa: ROR=20.45), hepatitis toxic (BDQ: ROR=28.65; DLM: ROR=21.42; Pa: ROR=90.67), bilirubin conjugated increased (BDQ: ROR=14.40; DLM: ROR=14.56; Pa: ROR=53.95), increased aspartate aminotransferase (BDQ: ROR=9.10; DLM: ROR=8.83; Pa: ROR=7.77), increased alanine aminotransferase (BDQ: ROR=5.68; DLM: ROR=5.54; Pa: ROR=8.92), drug-induced liver injury (BDQ: ROR=6.51; DLM: ROR=6.24; Pa: ROR=3.61) and anaemia (BDQ: ROR=6.54; DLM: ROR=5.75; Pa: ROR=4.83) remained common risks for them. However, in the other two contexts, only decreased haemoglobin (tuberculosis dataset: ROR=2.15; target dataset: ROR=1.03), which was more pronounced associated with DLM and prolonged ECG QT (tuberculosis dataset: ROR=2.46; target dataset: ROR=1.23), hepatotoxicity (tuberculosis dataset: ROR=1.74; target dataset: ROR=4.03) was more pronounced associated with BDQ, while other ADEs, like pancreatitis (tuberculosis dataset: ROR=4.54; target dataset: ROR=7.36), death (tuberculosis dataset: ROR=5.71; target dataset: ROR=2.47) and multiple organ dysfunction syndrome (tuberculosis dataset: ROR=1.46; target dataset: ROR=2.76), were worthy of attention associated with Pa apart from the common ADEs. The combination of linezolid (LZD) with the target drugs elevated risk signals for hepatotoxicity, haematologic toxicity and neurotoxicity. Subgroup analyses revealed that &lt;45 years exhibit a higher relative risk of hepatotoxicity (increased aspartate aminotransferase, aminotransferase increased, bilirubin conjugated increased and drug-induced liver injury), whereas peripheral neuropathy and decreased haemoglobin were observed in three target drugs. While \u226545 years are at a higher risk of prolonged ECG QT, females exhibited slightly higher signal strengths for hepatitis toxic, anaemia, and acute cardiac failure compared with males. While males aged \u226545 years receiving Pa may be at increased risk for pancreatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study highlights the differences in common ADEs of BDQ, DLM and Pa, as well as the differences in these ADEs among genders and age groups, providing valuable insights for clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-096515","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:30:19Z","timestamp":1765175419000},"page":"e096515","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5476-8491","authenticated-orcid":false,"given":"Liling","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4834-8677","authenticated-orcid":false,"given":"Li","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wuxi Fifth Hospital Affiliated to Jiangnan University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2431-5827","authenticated-orcid":false,"given":"Yating","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1514-0861","authenticated-orcid":false,"given":"Weiwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4978-6697","authenticated-orcid":false,"given":"Ruohan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"2026010703470397000_15.12.e096515.1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jgar.2022.09.001","article-title":"Pretomanid development and its clinical roles in treating tuberculosis","volume":"31","author":"Fekadu","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2026010703470397000_15.12.e096515.2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/ijmy.ijmy_41_24","article-title":"Postmortem for Intensified Missed Tuberculosis Case Finding in High Human Immunodeficiency Virus and Tuberculosis-burdened Settings in Sub-Saharan Africa among Adults\u2019 Population: Systematic Review and Meta-analysis","volume":"13","author":"Sindato","year":"2024","journal-title":"Int J Mycobacteriol"},{"key":"2026010703470397000_15.12.e096515.3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/cid\/ciad312","article-title":"Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease","volume":"77","author":"Haley","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026010703470397000_15.12.e096515.4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1874467215666220421130707","article-title":"Bedaquiline in Drug-Resistant Tuberculosis: A Mini-Review","volume":"16","author":"Singh","year":"2023","journal-title":"Curr Mol Pharmacol"},{"key":"2026010703470397000_15.12.e096515.5","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jac\/dkab505","article-title":"Delamanid or pretomanid? A Solomonic judgement!","volume":"77","author":"Mudde","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026010703470397000_15.12.e096515.6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1164\/rccm.202212-2262ED","article-title":"Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis","volume":"207","author":"Vel\u00e1squez","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010703470397000_15.12.e096515.7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","article-title":"Bedaquiline: Current status and future perspectives","volume":"25","author":"Khoshnood","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2026010703470397000_15.12.e096515.8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijid.2016.12.024","article-title":"New tuberculosis drug leads from naturally occurring compounds","volume":"56","author":"Quan","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2026010703470397000_15.12.e096515.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01891-2015"},{"key":"2026010703470397000_15.12.e096515.10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"2026010703470397000_15.12.e096515.11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026010703470397000_15.12.e096515.12","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1080240"},{"key":"2026010703470397000_15.12.e096515.13","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113515064"},{"key":"2026010703470397000_15.12.e096515.14","doi-asserted-by":"publisher","DOI":"10.1177\/1753465812452193"},{"key":"2026010703470397000_15.12.e096515.15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01202-20","article-title":"Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis","volume":"65","author":"Wang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026010703470397000_15.12.e096515.16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jctube.2023.100405","article-title":"Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis","volume":"34","author":"Ur Rehman","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026010703470397000_15.12.e096515.17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/ijmy.ijmy_178_22","article-title":"Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis","volume":"11","author":"Putra","year":"2022","journal-title":"Int J Mycobact"},{"key":"2026010703470397000_15.12.e096515.18","doi-asserted-by":"crossref","first-page":"106939","DOI":"10.1016\/j.ijantimicag.2023.106939","article-title":"The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation","volume":"62","author":"Jin","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026010703470397000_15.12.e096515.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.08.007"},{"key":"2026010703470397000_15.12.e096515.20","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciac876","article-title":"Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis","volume":"76","author":"Holmgaard","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026010703470397000_15.12.e096515.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-018-0906-1","article-title":"Effect of serum electrolytes within normal ranges on QTc prolongation: a cross-sectional study in a Chinese rural general population","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2026010703470397000_15.12.e096515.22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijid.2021.07.038","article-title":"Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis","volume":"110","author":"Li","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026010703470397000_15.12.e096515.23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.20473\/jr.v8-I.3.2022.140-146","article-title":"Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients","volume":"8","author":"Primadana","year":"2022","journal-title":"JR"},{"key":"2026010703470397000_15.12.e096515.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01462-2017"},{"key":"2026010703470397000_15.12.e096515.25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026010703470397000_15.12.e096515.26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jmii.2023.04.009","article-title":"Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study","volume":"56","author":"Kim","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"2026010703470397000_15.12.e096515.27","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab413","article-title":"QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study","volume":"8","author":"Isralls","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026010703470397000_15.12.e096515.28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/microorganisms9051074","article-title":"Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid","volume":"9","author":"Pecora","year":"2021","journal-title":"Microorganisms"},{"key":"2026010703470397000_15.12.e096515.29","doi-asserted-by":"crossref","unstructured":"Auchynka V , Kumar AMV , Hurevich H , et al . Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18. Monaldi Arch Chest Dis 2021;91. doi:10.4081\/monaldi.2021.1647","DOI":"10.4081\/monaldi.2021.1647"},{"key":"2026010703470397000_15.12.e096515.30","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ijid.2022.02.043","article-title":"Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis","volume":"124","author":"Nasiri","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026010703470397000_15.12.e096515.31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"2026010703470397000_15.12.e096515.32","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3201\/eid2310.170468","article-title":"Six-Month Response to Delamanid Treatment in MDR TB Patients","volume":"23","author":"Hewison","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2026010703470397000_15.12.e096515.33","doi-asserted-by":"crossref","first-page":"121375","DOI":"10.1016\/j.lfs.2023.121375","article-title":"Molecular mechanism for the involvement of CYP2E1\/NF-\u03baB axis in bedaquiline-induced hepatotoxicity","volume":"315","author":"Kotwal","year":"2023","journal-title":"Life Sci"},{"key":"2026010703470397000_15.12.e096515.34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40121-013-0009-3","article-title":"A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis","volume":"2","author":"Fox","year":"2013","journal-title":"Infect Dis Ther"},{"key":"2026010703470397000_15.12.e096515.35","doi-asserted-by":"crossref","first-page":"105956","DOI":"10.1016\/j.rmed.2020.105956","article-title":"Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and\/or delamanid in South Korea","volume":"167","author":"Kang","year":"2020","journal-title":"Respir Med"},{"key":"2026010703470397000_15.12.e096515.36","first-page":"91","article-title":"Delamanid: a review of its use in patients with multidrug-resistant tuberculosis","volume":"75","author":"Blair","year":"2015","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026010703470397000_15.12.e096515.37","doi-asserted-by":"crossref","first-page":"114066","DOI":"10.1016\/j.ejmech.2021.114066","article-title":"Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance","volume":"229","author":"Perveen","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2026010703470397000_15.12.e096515.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30100-2"},{"key":"2026010703470397000_15.12.e096515.39","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3201\/eid2310.170834","article-title":"Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis","volume":"23","author":"Maryandyshev","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2026010703470397000_15.12.e096515.40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00724-2015"},{"key":"2026010703470397000_15.12.e096515.41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijtb.2019.10.002","article-title":"Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis","volume":"67","author":"Salhotra","year":"2020","journal-title":"Indian J Tuberc"},{"key":"2026010703470397000_15.12.e096515.42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00930-2022","article-title":"Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney\/liver disease","volume":"60","author":"Chung","year":"2022","journal-title":"Eur Respir J"},{"key":"2026010703470397000_15.12.e096515.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2026010703470397000_15.12.e096515.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2026010703470397000_15.12.e096515.45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijtb.2019.11.012","article-title":"Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum","volume":"67","author":"Saroha","year":"2020","journal-title":"Indian J Tuberc"},{"key":"2026010703470397000_15.12.e096515.46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026010703470397000_15.12.e096515.47","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100290","article-title":"Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa","volume":"20","author":"Mohr-Holland","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026010703470397000_15.12.e096515.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058606","article-title":"Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant\/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol","volume":"12","author":"Padmapriyadarsini","year":"2022","journal-title":"BMJ Open"},{"key":"2026010703470397000_15.12.e096515.49","doi-asserted-by":"crossref","DOI":"10.52225\/narra.v3i3.402","article-title":"Efficacy of pretomanid-containing regiments for drug-resistant tuberculosis: A systematic review and meta-analysis of clinical trials","volume":"3","author":"Simanjuntak","year":"2023","journal-title":"Narra J"},{"key":"2026010703470397000_15.12.e096515.50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/picr.picr_1_23","article-title":"Effectiveness and safety of regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis","volume":"15","author":"Putra","year":"2024","journal-title":"Perspect Clin Res"},{"key":"2026010703470397000_15.12.e096515.51","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/cid\/ciac176","article-title":"Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs","volume":"75","author":"Huerga","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026010703470397000_15.12.e096515.52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01121-20","article-title":"An Exposure-Response Perspective on the Clinical Dose of Pretomanid","volume":"65","author":"Nedelman","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026010703470397000_15.12.e096515.53","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00112-09"},{"key":"2026010703470397000_15.12.e096515.54","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00106-09"},{"key":"2026010703470397000_15.12.e096515.55","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02033-21","article-title":"Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study","volume":"66","author":"Liu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026010703470397000_15.12.e096515.56","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3390\/ijms24043513","article-title":"Changes in Pancreatic Senescence Mediate Pancreatic Diseases","volume":"24","author":"Li","year":"2023","journal-title":"IJMS"},{"key":"2026010703470397000_15.12.e096515.57","unstructured":"U.S. Food and Drug Administration . Data from: FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files (2015 Q1-2023 Q4). Food and Drug Administration; 2024. Available: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-096515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:49:17Z","timestamp":1767786557000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-096515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,7]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2024-096515"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-096515","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}